Corneal Cross-linking as an Adjunct for The Management of Refractory Fungal Keratitis.


Journal

Middle East African journal of ophthalmology
ISSN: 0975-1599
Titre abrégé: Middle East Afr J Ophthalmol
Pays: India
ID NLM: 101521797

Informations de publication

Date de publication:
Historique:
received: 20 05 2019
revised: 15 04 2020
accepted: 19 09 2020
entrez: 5 4 2021
pubmed: 6 4 2021
medline: 29 5 2021
Statut: epublish

Résumé

To evaluate the effectiveness of ultraviolet (UV)-A/Riboflavin corneal cross-linking (CXL) for the treatment of the refractory cases of fungal keratitis. In this prospective interventional study, 9 patients with the diagnosis of fungal keratitis that were referred to our emergency eye center were included. These patients were resistant to conventional treatment and underwent therapeutic UV-A/Riboflavin CXL. Response to the treatment was considered as good if rapid epithelialization and rapid decrease in stromal infiltration was occurred after PACK-CXL, and poor when the emergency transplantation was necessary to eradicate the infection. Nine patients treated with CXL due to recalcitrant fungal keratitis. Culture of the corneal scrapings showed Although UV-A/Riboflavin CXL is not a definite treatment for all of the fungal keratitis, it seems promising in the management of some refractory cases.

Identifiants

pubmed: 33814816
doi: 10.4103/meajo.MEAJO_130_19
pii: MEAJO-27-204
pmc: PMC7993049
doi:

Substances chimiques

Cross-Linking Reagents 0
Photosensitizing Agents 0
Collagen 9007-34-5
Riboflavin TLM2976OFR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

204-209

Informations de copyright

Copyright: © 2021 Middle East African Journal of Ophthalmology.

Déclaration de conflit d'intérêts

There are no conflicts of interest.

Références

Curr Eye Res. 2005 Aug;30(8):613-20
pubmed: 16109640
Cornea. 2015 Apr;34(4):402-6
pubmed: 25710507
Cornea. 2009 Sep;28(8):856-9
pubmed: 19654533
Clin Exp Ophthalmol. 2007 May-Jun;35(4):324-9
pubmed: 17539783
Prikl Biokhim Mikrobiol. 1994 Jan-Feb;30(1):121-6
pubmed: 8146108
Transfusion. 2004 Jun;44(6):877-85
pubmed: 15157255
Water Res. 2001 Mar;35(4):1008-14
pubmed: 11235865
Cornea. 2008 Jun;27(5):590-4
pubmed: 18520510
Ophthalmologica. 2004 Mar-Apr;218(2):136-40
pubmed: 15004504
Klin Monbl Augenheilkd. 2000 Sep;217(3):190-3
pubmed: 11076351
J Refract Surg. 2008 Sep;24(7):S730-6
pubmed: 18811120
Vox Sang. 2000;78 Suppl 2:211-5
pubmed: 10938955
J Refract Surg. 2009 Sep;25(9):S803-6
pubmed: 19772255
Cornea. 2002 Aug;21(6):555-9
pubmed: 12131029
Clin Exp Ophthalmol. 2010 Mar;38(2):141-53
pubmed: 20398104
Eye (Lond). 2003 Nov;17(8):852-62
pubmed: 14631389
Cornea. 2010 Apr;29(4):409-11
pubmed: 20164744
Invest Ophthalmol Vis Sci. 2010 Aug;51(8):3950-3
pubmed: 20335618
Br J Ophthalmol. 2010 Aug;94(8):965-70
pubmed: 19666925
J Refract Surg. 2009 Sep;25(9):S799-802
pubmed: 19772254
Photochem Photobiol. 2004 Jul-Aug;80:15-21
pubmed: 15339215
Acta Derm Venereol. 1990;70(1):69-71
pubmed: 1967880
Bull World Health Organ. 2001;79(3):214-21
pubmed: 11285665
Eur J Ophthalmol. 2009 Mar-Apr;19(2):295-7
pubmed: 19253251
J Cataract Refract Surg. 2010 Feb;36(2):273-6
pubmed: 20152609
Br J Ophthalmol. 2010 May;94(5):660-1
pubmed: 20447971
Curr Opin Ophthalmol. 2008 Jul;19(4):302-6
pubmed: 18545011
Ophthalmology. 2009 Apr;116(4):615-23
pubmed: 19243833
Cornea. 2004 Jul;23(5):503-7
pubmed: 15220736
J Cataract Refract Surg. 2010 Mar;36(3):517-20
pubmed: 20202556
J Cataract Refract Surg. 2009 Mar;35(3):588-9
pubmed: 19251154
Transfus Apher Sci. 2007 Oct;37(2):131-7
pubmed: 17950672
Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3402-8
pubmed: 18408193
Cornea. 2009 May;28(4):474-6
pubmed: 19411973
Curr Eye Res. 2004 Jul;29(1):35-40
pubmed: 15370365
Int J Hematol. 2002 Aug;76 Suppl 2:253-7
pubmed: 12430933
Cornea. 2000 May;19(3):307-12
pubmed: 10832689
Cornea. 2010 Feb;29(2):235-8
pubmed: 20023590
Graefes Arch Clin Exp Ophthalmol. 2019 Jul;257(7):1443-1452
pubmed: 31041523

Auteurs

Shahram Bamdad (S)

Poostchi Ophthalmology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Mohammad R Khalili (MR)

Poostchi Ophthalmology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Amir Khosravi (A)

Poostchi Ophthalmology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Adel Attarzade (A)

Poostchi Ophthalmology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Hossein Movahedan (H)

Poostchi Ophthalmology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Mahmood Nejabat (M)

Poostchi Ophthalmology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH